Clinical significance and applications of (epi)lipidomics


To establish a roadmap for clinical translation of MS-based lipidomics by bringing together participants working in clinical diagnostic and laboratory medicine, clinicians, researchers involved in method development and validation, biostatisticians and commercial enterprises developing lipid standards and diagnostic kits. The main focus of WG3 is a network – and community – wide assessment of the putative implementation strategies of lipid derived markers in clinical workflows considering analytical and clinical performance, clinical and cost effectiveness, and impact.

Expected outcomes

  1. Standardization of preanalytical workflows for sample collection, biobanking, storage and management in clinical environment for biofluids and tissue samples
  2. Assessment of the inter-individual variability factors in clinical lipidomics including age, gender, ethnicity, diet and lifestyle, medication history and disease conditions
  3. Development of a workflow for the establishment of reference values for selected lipids
  4. Definition, assessment and promotion of reference materials to increase comparability of large scale lipidomic studies
  5. Development, optimization, implementation and exchange of biostatistics tools and machine learning algorithm for lipid biomarker discovery and validation in large clinical cohorts

WG3 Leader

Matej Orešič
University of Turku (Finland), and associate professor at Örebro University (Sweden)

WG3 Vice-leader

Margrét Thorsteinsdóttir
University of Iceland, Reykjavík, Iceland